Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Has Average Target Price of $41.25

Parabilis Medicines, Inc. (NASDAQ:PBLS) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $40.80.

Several equities analysts recently commented on PBLS shares. HC Wainwright initiated coverage on shares of Parabilis Medicines in a research report on Thursday, October 22nd. They issued a “buy” rating and a $40.00 price objective for the company. Canaccord Genuity Group initiated coverage on shares of Parabilis Medicines in a research note on Monday. They issued a “buy” rating and a $39.00 target price for the company. Finally, Weiss Ratings cut Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, November 2nd.

Parabilis Medicines Price Performance

Shares of NASDAQ PBLS opened at $29.65 on Monday. The stock’s fifty day moving average is $31.36. Parabilis Medicines has a 1-year low of $22.66 and a 1-year high of $42.49.

Parabilis Medicines (NASDAQ:PBLS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($2.16). The firm had revenue of $0.15 million for the quarter. As a group, equities analysts forecast that Parabilis Medicines will post -2.60 EPS for the current fiscal year.

Institutional Investors Weigh In On Parabilis Medicines

Several institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC increased its stake in Parabilis Medicines by 95.5% during the 3rd quarter. Parallel Advisors LLC now owns 1,075 shares of the company’s stock worth $35,000 after buying an additional 525 shares in the last quarter. Sterling Capital Management LLC acquired a new stake in shares of Parabilis Medicines in the third quarter worth approximately $35,000. Russell Investments Group Ltd. acquired a new stake in shares of Parabilis Medicines in the third quarter worth approximately $96,000. Persistent Asset Partners Ltd purchased a new stake in shares of Parabilis Medicines during the second quarter worth $113,000. Finally, Voya Investment Management LLC acquired a new stake in shares of Parabilis Medicines in the third quarter valued at about $241,000.

About Parabilis Medicines

Parabilis Medicines is a clinical-stage biopharmaceutical company developing medicines for diseases driven by proteins that have been difficult to target with conventional drugs. Its research focuses on macrocyclic peptides designed to address challenging protein interactions, including targets relevant to cancer. The company uses its proprietary Helicon platform to design these peptide-based drug candidates. Parabilis is based in Cambridge, Massachusetts, and was formerly known as Peptone. Parabilis was founded by Gregory Verdine, who serves as the company’s chief executive officer.